Literature DB >> 15462773

In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis.

S L Croft1.   

Abstract

The search for more effective drugs for the treatment of leishmaniasis and trypanosomiasis has increasingly involved the use of in vitro screens. These possess the immediate advantages of requiring only a few mg of compound for tests, providing for a large through-put of compounds with rapid results at lower costs, and requiring fewer animals. Models for the cultivation or maintenance in vitro of 'mammalian stages' of Leishmania and Trypanosoma cruzi have been available for many years but only in the last decade have satisfactory techniques for the cultivation of bloodstream forms of T. brucei been developed.

Entities:  

Year:  1986        PMID: 15462773     DOI: 10.1016/0169-4758(86)90157-2

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  14 in total

1.  Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening.

Authors:  Suman Gupta; Shyam Sundar; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.

Authors:  Alex G Peniche; Yaneth Osorio; Adam R Renslo; Doug E Frantz; Peter C Melby; Bruno L Travi
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing.

Authors:  M E Ibrahim; M Hag-Ali; A M el-Hassan; T G Theander; A Kharazmi
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

4.  A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.

Authors:  Diana Tegazzini; Rosario Díaz; Fernando Aguilar; Imanol Peña; Jesús L Presa; Vanessa Yardley; Julio J Martin; Jose M Coteron; Simon L Croft; Juan Cantizani
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

5.  Glucantime susceptibility of Leishmania promastigotes under variable growth conditions.

Authors:  E S Moreira; R M Soares; M de L Petrillo-Peixoto
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

Review 6.  Visceral leishmaniasis: experimental models for drug discovery.

Authors:  Suman Gupta
Journal:  Indian J Med Res       Date:  2011-01       Impact factor: 2.375

7.  Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis.

Authors:  Estefanía Calvo-Álvarez; Kostantinos Stamatakis; Carmen Punzón; Raquel Álvarez-Velilla; Ana Tejería; José Miguel Escudero-Martínez; Yolanda Pérez-Pertejo; Manuel Fresno; Rafael Balaña-Fouce; Rosa M Reguera
Journal:  PLoS Negl Trop Dis       Date:  2015-03-31

8.  Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.

Authors:  Sarah Hendrickx; Annelies Leemans; Annelies Mondelaers; Suman Rijal; Basudha Khanal; Jean-Claude Dujardin; Peter Delputte; Paul Cos; Louis Maes
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

9.  In vivo efficacy of gum obtained pistacia atlantica in experimental treatment of cutaneous leishmaniasis.

Authors:  M Taran; M Mohebali; J Esmaeli
Journal:  Iran J Public Health       Date:  2010-03-31       Impact factor: 1.429

10.  In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.

Authors:  Somayeh Sadeghi; Negar Seyed; Mohammad-Hossein Etemadzadeh; Saeid Abediankenari; Sima Rafati; Tahereh Taheri
Journal:  Korean J Parasitol       Date:  2015-08-25       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.